Loading…
Ginkgo Bioworks Holdings, Inc. is projected to rise to $10.60 by 2027, a +17% move from its current price of $9.09. DNA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $8.72 | $9.09 | $9.47 | -0.03% |
| Jul 13 | $8.56 | $9.08 | $9.64 | -0.06% |
| Jul 14 | $8.45 | $9.08 | $9.76 | -0.08% |
| Jul 15 | $8.35 | $9.08 | $9.87 | -0.11% |
| Jul 16 | $8.27 | $9.08 | $9.96 | -0.14% |
| Jul 17 | $8.19 | $9.07 | $10.05 | -0.17% |
| Jul 18 | $8.12 | $9.07 | $10.13 | -0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.12 | $9.07 | $10.13 | -0.20% |
| Week 2 | $7.75 | $9.05 | $10.58 | -0.39% |
| Week 3 | $7.46 | $9.04 | $10.94 | -0.59% |
| Week 4 | $7.23 | $9.02 | $11.25 | -0.79% |
| Week 5 | $7.03 | $9.00 | $11.52 | -0.98% |
| Week 6 | $6.86 | $8.98 | $11.77 | -1.18% |
| Week 7 | $6.69 | $8.96 | $12.00 | -1.38% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ginkgo Bioworks Holdings, Inc. operates in the Healthcare sector and builds a platform for cell engineering in the United States. It works through the Cell Engineering and Biosecurity segments to offer cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products.
The company also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, it pursues genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. Ginkgo Bioworks serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Ginkgo Bioworks Holdings, Inc. (DNA) is a biotechnology company focused on cell engineering with a platform spanning cell engineering R&D tools and services for multiple industries. The stock has a current price of $9.34 and a market capitalization of $610.13M, and it is ranked 2911 by market cap.
The near‑term outlook shows a flat to modest trajectory through 2026 with an average price of $9.34 and a neutral sentiment (ROI 0%). The forecast then shifts toward stronger upside in the late 2020s and into the 2030s, with multi‑year bullish momentum beginning in 2029 and continuing through 2050. Long‑term targets project substantial gains, including an average price of $15.10 in 2030 and $85.06 on average by 2050, with corresponding ROIs of 61.7% and 810.7%, respectively.
In the long run, the forecast envisions continued upside, with 2040 average price at $37.52 (ROI 301.7%) and 2050 average price at $85.06 (ROI 810.7%), signaling meaningful value expansion over time despite near‑term volatility.
A major floor 39.7% below — a decisive break under it would weaken the trend.
The nearest floor, 13.2% below — buyers have tended to step in here.
The nearest ceiling, 14.4% above — a clean break opens room to run.
A major ceiling 28.0% above — clearing it would confirm fresh momentum.
Key DNA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DNA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $9.47 | Sell | $9.46 | Sell |
| MA 10 | $9.84 | Sell | $9.54 | Sell |
| MA 20 | $9.28 | Sell | $9.37 | Sell |
| MA 50 | $8.91 | Buy | $8.90 | Buy |
| MA 100 | $8.13 | Buy | $8.72 | Buy |
| MA 200 | $9.29 | Sell | $9.20 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.55 | Neutral |
| Stoch RSI (14) | 0.63 | Buy |
| CCI (20) | -19.08 | Neutral |
| Williams %R (14) | -85.06 | Info |
| MACD (12,26,9) | -0.07 | Sell |
| ROC (12) | 2.60 | Buy |
| Bollinger %B (20,2) | 0.44 | Neutral |
| Stochastic %K (14) | 14.94 | Buy |
| TRIX (15) | 0.56 | Buy |
| Awesome (5,34) | 0.44 | Buy |
| Ultimate (7,14,28) | 42.08 | Neutral |
| Momentum (10) | -0.48 | Sell |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 9.10 | Sell |
| ADX (14) | 14.94 | Neutral |
| ATR (14) | 0.38 | Info |
The 30-day technical picture paints a bullish tilt with RSI(14) at 50 and the stock trading near key moving averages. The SMA50 is $8.82, while the SMA200 sits at $9.32, helping define near‑term support and resistance around a baseline price.
There is a defined near‑term support at $7.89 and a resistance at $10.40, with the 30‑day price range ranging from a low of $7.18 to a high of $12.15. The price action in the coming weeks may continue to oscillate within these levels as investors assess the evolving fundamentals and sentiment.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.48 | $9.09 | $12.31 | 0% | Neutral | |
| $8.03 | $10.60 | $15.04 | +17% | Neutral | |
| $7.96 | $11.00 | $16.43 | +21% | Bullish | |
| $8.05 | $11.56 | $17.99 | +27% | Bullish | |
| $10.56 | $15.68 | $25.24 | +73% | Bullish | |
| $13.03 | $19.97 | $33.10 | +120% | Bullish | |
| $13.88 | $21.91 | $37.27 | +141% | Bullish | |
| $13.58 | $22.06 | $38.41 | +143% | Bullish | |
| $13.71 | $22.88 | $40.69 | +152% | Bullish | |
| $14.92 | $25.56 | $46.38 | +181% | Bullish | |
| $21.26 | $41.19 | $81.10 | +353% | Bullish | |
| $43.57 | $96.82 | $214.13 | +965% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $5.48 | $9.09 | $11.18 | +0.00% |
| August 2026 | $7.73 | $9.26 | $11.48 | +1.86% |
| September 2026 | $7.32 | $8.86 | $11.17 | -4.32% |
| October 2026 | $7.25 | $8.87 | $11.33 | +0.07% |
| November 2026 | $7.59 | $9.35 | $12.08 | +5.43% |
| December 2026 | $7.59 | $9.42 | $12.31 | +0.82% |
Click any year to see its month-by-month DNA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Ginkgo Bioworks Holdings, Inc.'s 2026 outlook centres on $9.09, within a $5.48 to $12.31 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, DNA could reach as high as $15.04, with a base case around $10.60 and support toward $8.03 — roughly +17% from $9.09. A consolidation phase looks the most probable path here.
Expect DNA to range from $7.96 to $16.43 through 2028. The $11.00 average target implies a +21% move from current prices. That is up +4% on the projected 2027 average. Momentum favours further upside here.
The DNA price prediction for 2029 points to an average of $11.56 (low $8.05, high $17.99) — a potential gain of +27% on today's $9.09. Buyers look set to stay in control over this stretch.
In 2030, DNA is projected to trade between $10.56 and $25.24, averaging $15.68 — a potential gain of +73% from today's $9.09. That is up +36% on the projected 2029 average. Momentum favours further upside here.
Ginkgo Bioworks Holdings, Inc.'s 2031 outlook centres on $19.97, within a $13.03 to $33.10 range. That is up +27% on the projected 2030 average. That marks a +120% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, DNA could reach as high as $37.27, with a base case around $21.91 and support toward $13.88 — roughly +141% from $9.09. Momentum favours further upside here.
Expect DNA to range from $13.58 to $38.41 through 2033. The $22.06 average target implies a +143% move from current prices. That is up +1% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The DNA price prediction for 2034 points to an average of $22.88 (low $13.71, high $40.69) — a potential gain of +152% on today's $9.09. Momentum favours further upside here.
In 2035, DNA is projected to trade between $14.92 and $46.38, averaging $25.56 — a potential gain of +181% from today's $9.09. That is up +12% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Ginkgo Bioworks Holdings, Inc.'s 2040 outlook centres on $41.19, within a $21.26 to $81.10 range. That is up +61% on the projected 2035 average. That marks a +353% change versus current levels. Momentum favours further upside here.
By 2050, DNA could reach as high as $214.13, with a base case around $96.82 and support toward $43.57 — roughly +965% from $9.09. Buyers look set to stay in control over this stretch.
Investing $1,000 in DNA today (≈ 110.011001 DNA) could be worth
$10,651.05
+$9,651.05 (+965%) by 2050 · US Dollar
Based on the average projected DNA price of $96.82 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DNAwould be worth at today's price.
$1,000 invested in DNA on Jul 10, 2025 (≈ 92.678406 DNA) would be worth
$842.45
-$157.55 (-15.8%) today · 0.84× · US Dollar
Based on a DNA entry price of $10.79 vs. today's $9.09.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $10.4 | $874.04 | -12.6% |
| 1 month ago | $7.94 | $1,144.84 | +14.5% |
| 3 months ago | $6.45 | $1,409.3 | +40.9% |
| 6 months ago | $9.56 | $950.84 | -4.9% |
| 1 year ago | $10.79 | $842.45 | -15.8% |
| All time (5.0y) ago | $398 | $22.84 | -97.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DNA forecast.
Our base-case forecast reaches $18.00 around 2031.
Implied market cap at $18.00: $960.5M
The year‑by‑year forecast outlines a path from neutral near term to strong bullish momentum over the longer horizon. In 2026 the avg price is $9.34 with a neutral sentiment and 0% ROI, followed by 2027 at $10.70 (14.6% ROI) and 2028 at $11.03 (18.1% ROI).
From 2029 onward, the outlook turns bullish, with 2029 avg $11.35 (21.5% ROI) and 2030 avg $15.10 (61.7% ROI). The bullish trend continues through 2031 ($19.06, 104.1%), 2032 ($20.66, 121.2%), 2033 ($20.94, 124.2%), 2034 ($21.65, 131.8%), and 2035 ($23.68, 153.5%). In the longer horizon, 2040 shows an avg of $37.52 (301.7% ROI) and 2050 an avg of $85.06 (810.7% ROI).
These figures suggest meaningful upside potential over the coming decades, but they are estimates and not guarantees. Investors should consider the inherent uncertainty and the prospect of volatility given the long forecasting horizon and potential market dynamics that could alter outcomes.
Tap a question to reveal the answer.
Average price $15.10; min $10.29; max $24.03; ROI 61.7%; sentiment BULLISH.
Long‑term outlook shows bullish momentum from 2029 onward, with 2030 average $15.10 and 2050 average $85.06 (ROI up to 810.7%). Near term (2026–2028) is neutral, so forecasts imply upside but are not guaranteed.
Yes. The forecast for 2031 lists max $31.20, and 2032 max $34.68, 2033 max $35.95, 2034 max $37.95, and 2035 max $42.31, indicating potential to exceed $31.20 in 2031.
Low $7.18; High $12.15.
Ginkgo Bioworks Holdings, Inc. Community Discussion
0Share your Ginkgo Bioworks Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.